ERBB2 and breast carcinoma: Correspondingly, ErbB2 targeting has proved an effective approach in the battle against ErbB2-positive breast cancers, and current therapies approved by the FDA include ErbB2-directed antibodies and small molecule tyrosine kinase inhibitors [3].